← Eichor
Study identifier: NCT04804007 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Maintenance Oral Etoposide or Observation Following High-dose Chemo for GCT

Condition: Germ Cell Tumor · Non-seminomatous Germ Cell Tumor · Ovarian Germ Cell Tumor  ·  Sponsor: Nabil Adra

PhasePhase 2
Planned participants64
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

This is an open label randomized phase II trial of maintenance oral etoposide vs. observation in patinets with relapsed GCT treated with high-dose chemotherapy (HDCT) and peripheral-blood stem-cell transplant (PBSCT).

This description comes directly from the study's public registry record.

Talk to the study team

Christin Snow, RN  ·  317-274-5830  ·  chsnow@iu.edu

Always discuss trial participation with your own doctor first.

Locations (1)

Indiana University Melvin & Bren Simon Cancer CenterIndianapolis, Indiana, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT04804007